An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini

BACKGROUND: Dolutegravir (DTG) is an Integrase Strand Transfer Inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV infection. It is available in a number of pharmaceutical preparations including the fixed-dose combination (TLD) containing tenofovir (3...

Descripción completa

Detalles Bibliográficos
Autores principales: Duga, Alemayehu L., Magongo, Sibongile, Nhlabatsi, Siphesihle, Ladwar, Denis O., Härmark, Linda, Rolfes, Leàn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694599/
https://www.ncbi.nlm.nih.gov/pubmed/36424607
http://dx.doi.org/10.1186/s12981-022-00481-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694599/
https://www.ncbi.nlm.nih.gov/pubmed/36424607
http://dx.doi.org/10.1186/s12981-022-00481-0

Ejemplares similares